Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026
Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026
Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Fineline Cube Jan 13, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Deals

Innovent Biologics Expands Partnership with Synaffix for New ADC Development

Fineline Cube Dec 7, 2023

Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...

Company Deals

Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection

Fineline Cube Dec 7, 2023

Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...

Company

Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition

Fineline Cube Dec 6, 2023

Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for...

Company Drug

Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Dec 6, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...

Company Deals

AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience

Fineline Cube Dec 6, 2023

AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in...

Company

J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth

Fineline Cube Dec 6, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,...

Company Drug

China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication

Fineline Cube Dec 6, 2023

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Company Medical Device

Sinocare Inc’s Blood Glucose Monitoring System Earns US FDA Approval

Fineline Cube Dec 6, 2023

Sinocare Inc (SHE: 300298), a Chinese medical device company, has announced that it has received...

Company Drug

Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy

Fineline Cube Dec 6, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has received approval from the...

Company Drug

Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038

Fineline Cube Dec 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug

Fineline Cube Dec 6, 2023

Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab

Fineline Cube Dec 6, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...

Company Drug

China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval

Fineline Cube Dec 6, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment

Fineline Cube Dec 6, 2023

Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a...

Company Medical Device

Sino Medical Secures Market Approval in Taiwan for NC Rockstar Coronary Catheter

Fineline Cube Dec 6, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that its NC Rockstar non-compliant coronary...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod

Fineline Cube Dec 5, 2023

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug

Fineline Cube Dec 5, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...

Company Drug

Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide

Fineline Cube Dec 5, 2023

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...

Company Drug

Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Dec 5, 2023

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall

Fineline Cube Dec 5, 2023

WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...

Posts pagination

1 … 375 376 377 … 608

Recent updates

  • China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs
  • RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
  • Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China
  • Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
  • Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.